Transient Increase in Circulating Basophils and Eosinophils in Dupilumab-associated Conjunctivitis in Patients with Atopic Dermatitis
DOI:
https://doi.org/10.2340/00015555-3842Keywords:
atopic dermatitis, basophils, eosinophils, dupilumab associated conjunctivitis, dry eyeAbstract
Abstract is missing (Short communication)
Downloads
References
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019; 181: 459-473.
DOI: https://doi.org/10.1111/bjd.17869
Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019; 81: 143-151.
DOI: https://doi.org/10.1016/j.jaad.2019.02.053
Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol 2020; 104: 776-779.
DOI: https://doi.org/10.1136/bjophthalmol-2019-315010
Takamura E, Uchio E, Ebihara N, Ohno S, Ohashi Y, Okamoto S, et al. Japanese guidelines for allergic conjunctival diseases 2017. Allergol Int 2017; 66: 220-229.
DOI: https://doi.org/10.1016/j.alit.2016.12.004
Toda I, Shimazaki J, Tsubota K. Dry eye with only decreased tear break-up time is sometimes associated with allergic conjunctivitis. Ophthalmology 1995; 102: 302-309.
DOI: https://doi.org/10.1016/S0161-6420(95)31024-X
Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC. Atopic keratoconjunctivitis: A review. J Am Acad Dermatol 2014; 70: 569-575.
DOI: https://doi.org/10.1016/j.jaad.2013.10.036
Dogru M, Katakami C, Nakagawa N, Tetsumoto K, Yamamoto M. Impression cytology in atopic dermatitis. Ophthalmology 1998; 105: 1478-1484.
DOI: https://doi.org/10.1016/S0161-6420(98)98032-0
Touhouche AT, Cassagne M, Berard E, Giordano-Labadie F, Didier A, Fournie P, et al. Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. J Eur Acad Dermatol Venereol 2021; 35: 172-179.
DOI: https://doi.org/10.1111/jdv.16724
Bakker DS, Ariens LFM, van Luijk C, van der Schaft J, Thijs JL, Schuttelaar MLA, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. Br J Dermatol 2019; 180: 1248-1249.
DOI: https://doi.org/10.1111/bjd.17538
Voorberg AN, den Dunnen WFA, Wijdh RHJ, de Bruin-Weller MS, Schuttelaar MLA. Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis. J Eur Acad Dermatol Venereol 2020; 34: e64-e66.
Kessing SV. Mucous gland system of the conjunctiva. A quantitative normal anatomical study. Acta Ophthalmol (Copenh) 1968: Suppl 95: 91+.
Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol 2020; 182: 1120-1135.
DOI: https://doi.org/10.1111/bjd.18434
Imai Y, Yasuda K, Nagai M, Kusakabe M, Kubo M, Nakanishi K, et al. IL-33-induced atopic dermatitis-like inflammation in mice is mediated by group 2 innate lymphoid cells in concert with basophils. J Invest Dermatol 2019; 139: 2185-2194.e3.
Published
How to Cite
License
Copyright (c) 2021 Michie Katsuta, Yozo Ishiuji, Hiroyuki Matsuzaki, Ken-ichi Yasuda, Budiman Kharma, Yoshimasa Nobeyama, Takaaki Hayashi, Yoshiki Tokura, Akihiko Asahina
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
